Patients using GLP-1 drugs had no difference in the odds of postoperative aspiration pneumonia versus non-users. Preoperative ...

Weight-loss drugs are changing the way people grocery shop and eat. But those spending habits don't necessarily last.

A boost for the category, and perhaps even a change in the way products are marketed, is anticipated based on research ...

This month pharmacies will no longer be allowed to sell lower-cost compounded versions of the anti-obesity drug tirzepatide — ...

Expanding coverage and access to GLPs can be beneficial for all with the cooperation of multiple parties in health care.

Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within 1 year.

GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.

Novo Nordisk is taking a page out of Eli Lilly’s playbook as the two GLP-1 drugmakers work to fend off compounding pharmacies ...

Novo Nordisk, the manufacturer of Weggovy, is growing its offerings by creating NovoCare Pharmacy, a direct-to-patient (DTP) ...

The offer may show employers how hard drug manufacturers will compete based on price, in at least some situations.

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

After earmarking a major chunk of change last year to bulk up in peptide production, European CDMO CordenPharma is putting ...